NovaDigm raises $14m for fungal, bacterial vaccines
This article was originally published in Scrip
Executive Summary
NovaDigm Therapeutics raised $14m in Series B venture capital to finance the development of vaccines against fungal and bacterial infections, including an ongoing Phase Ib/IIa clinical trial for the NDV-3 vaccine to treat women with recurrent vulvovaginal candidiasis (RVVC), or vaginal yeast infections.